Silvina Pugliese, MD
Dermatology · Jamaica
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 4
Offices
4 locations · New York University · 5,925 clinicians in this group
Hospitals listed: NYU Langone Hospitals · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pugliese’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A118309 · Current
Licensed to practise in California · since 2011 · expires 2027-03-31 · Boston University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- NYU Langone HospitalsNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of NYU Langone Health, which runs 5 hospitalsHome of Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 11.9 (10.8 to 13.2) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.56 to 0.78), Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 110.18 (84.1 to 136.26) · 561 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 2.66 (1.81 to 3.51) · 16,112 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 3.24 (1.36 to 5.12) · 9,218 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.56 (1.28 to 3.83) · 9,540 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.39, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.097, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.529, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.7 (3.1 to 4.4) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.5 (9.1 to 12.3) · 10,521 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.7 to 0.8) · 6,063 cases, Jan 2024 – Dec 2024
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for NYU Langone Hospitals
Behind the star rating — Deaths: 8 better, 0 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 1 worse of 8 measures. Readmissions: 8 better, 1 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.9 (10.8 to 13.2) · 2,678 cases | Worse | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.56 to 0.78) | Better | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 110.18 (84.1 to 136.26) · 561 cases | Better | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.66 (1.81 to 3.51) · 16,112 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.24 (1.36 to 5.12) · 9,218 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.56 (1.28 to 3.83) · 9,540 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.097 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.529 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.7 (3.1 to 4.4) · 2,678 cases | Better | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.5 (9.1 to 12.3) · 10,521 cases | Better | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.7 to 0.8) · 6,063 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.48 (0.95 to 2.01) · 9,995 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 331 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.2 · 532 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 6.7 · 547 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.2 · 2,910 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 8 · 4,115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.4 · 1,351 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 1.6 · 23,286 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0.01 to 0.24) · 48,461 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.12 to 0.34) · 50,693 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0.66 to 2.11) · 9,390 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.99 to 2.59) · 12,979 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.62 (0.53 to 2.72) · 3,510 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.38 to 0.82) · 40,829 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.8 · 3,298 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.091 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.859 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.3 · 667 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.7 · 4,060 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -23.8 · 603 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.8 · 3,334 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.5 · 4,338 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 5,069 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 3.7 · 3,383 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 6.8 · 386 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 820 cases | None | Jul 2023 – Jun 2025 |
What patients said (10,034 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$111,525
Medicare paid this office $111,525 for 680 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 175 | $23,042 | $88 |
| Short return visit (20+ min) | 213 | $17,656 | $60 |
| New patient visit (45+ min) | 76 | $9,202 | $121 |
| Destruction of precancer skin growth, 1 growth | 114 | $7,155 | $46 |
| Long return visit (40+ min) | 35 | $6,215 | $129 |
See all 19 services
| Return visit (30+ min) | 175 | $23,042 | $88 |
| Short return visit (20+ min) | 213 | $17,656 | $60 |
| New patient visit (45+ min) | 76 | $9,202 | $121 |
| Destruction of precancer skin growth, 1 growth | 114 | $7,155 | $46 |
| Long return visit (40+ min) | 35 | $6,215 | $129 |
| Destruction of skin growth, 1-14 growths | 75 | $5,884 | $67 |
| New patient visit (30+ min) | 76 | $5,438 | $72 |
| Biopsy of related skin growth, first growth | 134 | $4,454 | $26 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 137 | $4,062 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $2,971 | $102 |
| New patient visit (60+ min) | 18 | $2,886 | $160 |
| Destruction of precancer skin growth, 15 or more growths | 23 | $2,628 | $80 |
| Biopsy of related skin growth, each additional growth | 65 | $2,326 | $19 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,213 | $116 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 102 | $1,752 | $15 |
| Punch biopsy, first skin growth | 31 | $1,232 | $39 |
| Destruction of precancer skin growth, 2-14 growths | 96 | $1,158 | $2 |
| Punch biopsy, each additional skin growth | 22 | $571 | $22 |
| Punch biopsy, first skin growth | 12 | $506 | $42 |
Procedures Medicare counted
| Removal of skin lesions | 251 | More than 81% of doctors who do this |
| Skin biopsy | 229 | More than 87% of doctors who do this |
Who their Medicare patients are
680 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 13% · Women 54% · Also on Medicaid 25% · Health risk score 2.20. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 69% · Chronic kidney disease 34% · Cancer 34% · Diabetes 28% · Coronary heart disease 25% · Atrial fibrillation 21% · Depression 19% · Heart failure 17% · COPD 14% · Dementia 9% · Stroke 9%.
The office billed $526,708, Medicare allowed $146,072 and paid $111,525; for 2,504 services of 38 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 680 | 2,504 | 73 | 2.20 | $526,708 | $111,525 |
| 2023 | 480 | 1,996 | 73 | 2.08 | $373,470 | $80,698 |
| 2022 | 377 | 1,608 | 73 | 1.74 | $264,198 | $61,089 |
| 2021 | 251 | 932 | 72 | 1.84 | $198,160 | $43,823 |
| 2020 | 202 | 690 | 72 | 2.15 | $123,776 | $24,603 |
| 2019 | 306 | 1,331 | 71 | 2.16 | $176,306 | $52,640 |
| 2018 | 333 | 1,375 | 71 | 2.13 | $152,201 | $48,757 |
| 2017 | 393 | 1,433 | 70 | 1.82 | $201,290 | $59,377 |
| 2016 | 283 | 928 | 71 | 2.02 | $150,170 | $44,982 |
| 2015 | 229 | 859 | 72 | 1.90 | $126,196 | $38,942 |
| 2014 | 96 | 334 | 71 | 1.23 | $39,912 | $16,563 |
| 2013 | 40 | 128 | 75 | 1.02 | $10,335 | $7,553 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 130 | $15,806 | $84 |
| Short return visit (20+ min) | 144 | $11,424 | $55 |
| Long return visit (40+ min) | 53 | $7,505 | $125 |
| Destruction of precancer skin growth, 1 growth | 111 | $7,179 | $46 |
| New patient visit (45+ min) | 57 | $6,643 | $117 |
| Destruction of skin growth, 1-14 growths | 62 | $4,884 | $64 |
| Biopsy of related skin growth, first growth | 117 | $3,575 | $24 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 111 | $3,550 | $31 |
| New patient visit (30+ min) | 41 | $2,923 | $71 |
| Destruction of precancer skin growth, 15 or more growths | 22 | $2,737 | $91 |
| New patient visit (60+ min) | 14 | $2,300 | $164 |
| Biopsy of related skin growth, each additional growth | 57 | $1,913 | $20 |
| Punch biopsy, first skin growth | 31 | $1,328 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 99 | $1,214 | $2 |
| Punch biopsy, each additional skin growth | 17 | $466 | $23 |
2022: 17 services
| Return visit (30+ min) | 103 | $11,842 | $84 |
| Short return visit (20+ min) | 150 | $11,134 | $54 |
| New patient visit (45+ min) | 49 | $5,901 | $120 |
| Destruction of precancer skin growth, 1 growth | 85 | $5,275 | $43 |
| Destruction of skin growth, 1-14 growths | 52 | $3,816 | $61 |
| New patient visit (30+ min) | 51 | $3,633 | $71 |
| Long return visit (40+ min) | 22 | $3,334 | $123 |
| Biopsy of related skin growth, first growth | 88 | $2,709 | $24 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,712 | $90 |
| Biopsy of related skin growth, each additional growth | 46 | $1,592 | $19 |
| Destruction of precancer skin growth, 15 or more growths | 15 | $1,471 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,122 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $973 | $61 |
| Destruction of precancer skin growth, 2-14 growths | 75 | $965 | $2 |
| Punch biopsy, first skin growth | 27 | $952 | $35 |
| Punch biopsy, each additional skin growth | 20 | $533 | $23 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 11 | $355 | $32 |
2021: 15 services
| Return visit (30+ min) | 89 | $10,640 | $85 |
| Short return visit (20+ min) | 106 | $8,239 | $58 |
| New patient visit (45+ min) | 37 | $4,449 | $120 |
| Destruction of precancer skin growth, 1 growth | 51 | $2,594 | $47 |
| New patient visit (30+ min) | 32 | $2,375 | $74 |
| Destruction of skin growth, 1-14 growths | 24 | $2,150 | $65 |
| Biopsy of related skin growth, first growth | 65 | $1,992 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,814 | $95 |
| Long return visit (40+ min) | 11 | $1,552 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,461 | $66 |
| Punch biopsy, first skin growth | 25 | $1,134 | $42 |
| Biopsy of related skin growth, each additional growth | 32 | $873 | $19 |
| Short return visit | 15 | $545 | $32 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $446 | $2 |
| Punch biopsy, each additional skin growth | 15 | $379 | $24 |
2020: 14 services
| Return visit (30+ min) | 65 | $4,636 | $60 |
| Short return visit (20+ min) | 54 | $2,683 | $42 |
| Return visit (30+ min) | 22 | $1,532 | $64 |
| Long return visit (40+ min) | 12 | $1,337 | $103 |
| Destruction of precancer skin growth, 1 growth | 31 | $1,260 | $36 |
| Destruction of skin growth, 1-14 growths | 15 | $1,127 | $66 |
| New patient visit (30+ min) | 17 | $900 | $53 |
| Biopsy of related skin growth, first growth | 34 | $893 | $25 |
| Short return visit (20+ min) | 16 | $845 | $47 |
| New patient visit (15+ min) | 19 | $747 | $39 |
| Destruction of precancer skin growth, 1 growth | 15 | $723 | $48 |
| Biopsy of related skin growth, each additional growth | 15 | $359 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 27 | $268 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $98 | $2 |
2019: 24 services
| Return visit (30+ min) | 69 | $6,915 | $71 |
| Return visit (30+ min) | 59 | $4,729 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,151 | $94 |
| Long return visit (40+ min) | 26 | $3,130 | $98 |
| Short return visit (20+ min) | 55 | $3,011 | $44 |
| New patient visit (45+ min) | 25 | $2,916 | $117 |
| Destruction of precancer skin growth, 1 growth | 45 | $2,637 | $45 |
| Short return visit (20+ min) | 39 | $2,368 | $46 |
| Destruction of precancer skin growth, 1 growth | 30 | $2,200 | $48 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,112 | $66 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,794 | $90 |
| Punch biopsy, first skin growth | 32 | $1,583 | $44 |
| New patient visit (30+ min) | 23 | $1,577 | $69 |
| Biopsy of related skin growth, first growth | 49 | $1,432 | $25 |
| New patient visit (30+ min) | 23 | $1,357 | $59 |
| Destruction of skin growth, 1-14 growths | 19 | $1,275 | $64 |
| Destruction of skin growth, 1-14 growths | 17 | $1,227 | $68 |
| Biopsy of related skin growth, first growth | 29 | $877 | $25 |
| Biopsy of related skin growth, each additional growth | 14 | $619 | $21 |
| Punch biopsy, each additional skin growth | 22 | $603 | $25 |
| Biopsy of related skin growth, each additional growth | 15 | $526 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $522 | $2 |
| Punch biopsy, first skin growth | 11 | $511 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $326 | $2 |
2018: 21 services
| Return visit (30+ min) | 70 | $6,601 | $67 |
| Return visit (30+ min) | 51 | $3,876 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,745 | $94 |
| Short return visit (20+ min) | 71 | $3,738 | $41 |
| Short return visit (20+ min) | 51 | $3,269 | $45 |
| Destruction of precancer skin growth, 1 growth | 50 | $2,568 | $40 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 28 | $2,515 | $90 |
| Long return visit (40+ min) | 20 | $2,514 | $97 |
| Biopsy of single growth of skin and/or tissue | 59 | $2,371 | $34 |
| Destruction of precancer skin growth, 1 growth | 35 | $2,363 | $46 |
| Biopsy of single growth of skin and/or tissue | 59 | $1,948 | $29 |
| New patient visit (30+ min) | 32 | $1,775 | $55 |
| Destruction of skin growth, 1-14 growths | 23 | $1,561 | $56 |
| New patient visit (45+ min) | 13 | $1,499 | $115 |
| Destruction of skin growth, 1-14 growths | 18 | $1,372 | $62 |
| New patient visit (30+ min) | 19 | $1,291 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $981 | $65 |
| Biopsy of each additional growth of skin and/or tissue | 29 | $871 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $450 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 14 | $450 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 26 | $429 | $2 |
2017: 19 services
| Return visit (30+ min) | 88 | $8,828 | $68 |
| Return visit (30+ min) | 97 | $7,529 | $63 |
| New patient visit (45+ min) | 45 | $5,137 | $114 |
| Long return visit (40+ min) | 42 | $4,882 | $100 |
| New patient visit (30+ min) | 67 | $4,198 | $63 |
| Short return visit (20+ min) | 52 | $3,581 | $45 |
| Destruction of skin growth, 1-14 growths | 39 | $3,264 | $62 |
| Destruction of precancer skin growth, 1 growth | 54 | $2,858 | $45 |
| Short return visit (20+ min) | 55 | $2,765 | $43 |
| Biopsy of single growth of skin and/or tissue | 59 | $2,515 | $38 |
| Biopsy of single growth of skin and/or tissue | 64 | $2,190 | $30 |
| Destruction of precancer skin growth, 1 growth | 26 | $1,304 | $40 |
| New patient visit (30+ min) | 19 | $1,290 | $68 |
| Destruction of skin growth, 1-14 growths | 14 | $1,094 | $68 |
| Biopsy of each additional growth of skin and/or tissue | 35 | $909 | $22 |
| Biopsy of each additional growth of skin and/or tissue | 25 | $556 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 45 | $518 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 21 | $297 | $2 |
| Short return visit | 13 | $226 | $17 |
2016: 19 services
| Return visit (30+ min) | 93 | $7,887 | $66 |
| Return visit (30+ min) | 80 | $7,826 | $68 |
| New patient visit (45+ min) | 51 | $5,728 | $112 |
| Long return visit (40+ min) | 24 | $2,999 | $97 |
| New patient visit (30+ min) | 41 | $2,470 | $60 |
| Biopsy of single growth of skin and/or tissue | 56 | $2,147 | $35 |
| New patient visit (45+ min) | 20 | $2,011 | $101 |
| Destruction of precancer skin growth, 1 growth | 42 | $1,928 | $44 |
| Biopsy of single growth of skin and/or tissue | 45 | $1,833 | $38 |
| Destruction of precancer skin growth, 1 growth | 28 | $1,418 | $46 |
| Destruction of skin growth, 1-14 growths | 17 | $1,234 | $62 |
| Long return visit (40+ min) | 11 | $1,189 | $99 |
| New patient visit (30+ min) | 12 | $814 | $68 |
| Destruction of skin growth, 1-14 growths | 11 | $748 | $62 |
| Biopsy of each additional growth of skin and/or tissue | 26 | $657 | $23 |
| Short return visit (20+ min) | 13 | $638 | $46 |
| Biopsy of each additional growth of skin and/or tissue | 18 | $499 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 28 | $288 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 19 | $149 | $2 |
2015: 10 services
| Return visit (30+ min) | 95 | $9,693 | $70 |
| New patient visit (45+ min) | 55 | $6,319 | $115 |
| New patient visit (30+ min) | 71 | $4,688 | $66 |
| Biopsy of single growth of skin and/or tissue | 81 | $3,480 | $38 |
| Short return visit (20+ min) | 53 | $3,068 | $45 |
| Destruction of precancer skin growth, 1 growth | 50 | $2,623 | $45 |
| Long return visit (40+ min) | 18 | $2,089 | $99 |
| Destruction of skin growth, 1-14 growths | 23 | $1,836 | $68 |
| Biopsy of each additional growth of skin and/or tissue | 38 | $1,018 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 37 | $446 | $2 |
2014: 5 services
| New patient visit (30+ min) | 27 | $1,823 | $68 |
| Short return visit (20+ min) | 25 | $1,731 | $49 |
| Biopsy of single growth of skin and/or tissue | 17 | $1,306 | $77 |
| Short return visit (20+ min) | 16 | $1,228 | $45 |
| Biopsy of single growth of skin and/or tissue | 24 | $898 | $37 |
2013: 4 services
| Biopsy of single growth of skin and/or tissue | 18 | $1,622 | $85 |
| Short return visit (20+ min) | 24 | $1,573 | $58 |
| New patient visit (30+ min) | 17 | $1,434 | $84 |
| Destruction of precancer skin growth, 1 growth | 11 | $515 | $47 |
Medicaid work
$1,773 in 2024
Medicaid paid $1,773 for 29 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 17 | $1,264 |
| Short return visit (20+ min) | 12 | $510 |
| 2024 | 29 | 2 | 17 | $1,773 |
| 2023 | 71 | 2 | 15 | $2,552 |
| 2022 | 42 | 2 | 15 | $1,842 |
| 2020 | 37 | 2 | 22 | $1,096 |
| 2019 | 12 | 1 | 12 | $424 |
| 2018 | 147 | 3 | 26 | $5,484 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 42 | $1,747 |
| Short return visit (20+ min) | 29 | $805 |
2022
| Return visit (30+ min) | 29 | $1,663 |
| Short return visit (20+ min) | 13 | $178 |
2020
| Short return visit (20+ min) | 24 | $612 |
| Return visit (30+ min) | 13 | $484 |
2019
| Return visit (30+ min) | 12 | $424 |
2018
| Short return visit (20+ min) | 97 | $3,188 |
| Return visit (30+ min) | 38 | $1,449 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 12 | $847 |
Drugs they prescribed that Part D paid
$447,096
Pharmacies billed $447,096 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,054) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
990 generic and 64 brand-name prescriptions · $447,096 in drug cost · 35 antibiotic prescriptions to 29 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Taltz | 14 | $99,241 | $7,089 |
| Cosentyx Sensoready (2 Pens) | 12 | $83,117 | $6,926 |
| Fluorouracil | 56 | $3,603 | $64 |
| Calcipotriene | 11 | $3,439 | $313 |
| Clobetasol Propionate | 46 | $3,134 | $68 |
See all 31 drugs
| Taltz | 14 | $99,241 | $7,089 |
| Cosentyx Sensoready (2 Pens) | 12 | $83,117 | $6,926 |
| Fluorouracil | 56 | $3,603 | $64 |
| Calcipotriene | 11 | $3,439 | $313 |
| Clobetasol Propionate | 46 | $3,134 | $68 |
| Ketoconazole | 113 | $2,337 | $21 |
| Tacrolimus | 25 | $2,248 | $90 |
| Triamcinolone Acetonide | 106 | $1,497 | $14 |
| Tretinoin | 18 | $1,488 | $83 |
| Desonide | 26 | $1,182 | $45 |
| Clindamycin Phosphate | 24 | $915 | $38 |
| Ciclopirox | 26 | $867 | $33 |
| Fluocinolone Acetonide | 15 | $775 | $52 |
| Fluocinolone Acetonide | 14 | $753 | $54 |
| Clindamycin-Benzoyl Peroxide | 16 | $716 | $45 |
| Minoxidil | 64 | $642 | $10 |
| Gentamicin Sulfate | 14 | $637 | $46 |
| Metronidazole | 13 | $532 | $41 |
| Hydroxyzine | 23 | $526 | $23 |
| Ciclopirox | 44 | $500 | $11 |
| Valacyclovir | 12 | $411 | $34 |
| Mupirocin | 63 | $408 | $6 |
| Hydroxychloroquine Sulfate | 16 | $401 | $25 |
| Doxepin | 12 | $365 | $30 |
| Fluocinonide | 17 | $330 | $19 |
| Hydrocortisone | 52 | $318 | $6 |
| Doxycycline Hyclate | 20 | $309 | $15 |
| Nystatin | 13 | $291 | $22 |
| Gabapentin | 24 | $170 | $7 |
| Prednisone | 16 | $120 | $8 |
| Terbinafine | 11 | $46 | $4 |
Year by year
| 2024 | 1,054 | 282 | 0% (0) | 6% | $447,096 |
| 2023 | 843 | 231 | None | 9% | $504,412 |
| 2022 | 647 | 170 | None | 9% | $321,351 |
| 2021 | 414 | 113 | 0% (0) | 16% | $268,203 |
| 2020 | 376 | 113 | 0% (0) | 9% | $154,318 |
| 2019 | 443 | 150 | 0% (0) | 8% | $74,781 |
| 2018 | 530 | 168 | 0% (0) | 12% | $94,077 |
| 2017 | 543 | 189 | 0% (0) | 10% | $70,455 |
| 2016 | 420 | 143 | None | 14% | $28,396 |
| 2015 | 293 | 116 | None | 15% | $38,047 |
| 2014 | 281 | 105 | 0% (0) | None | $60,568 |
| 2013 | 178 | 90 | 0% (0) | None | $48,057 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Taltz | 13 | $87,764 | $6,751 |
| Calcipotriene | 25 | $27,556 | $1,102 |
| Fluorouracil | 51 | $4,832 | $95 |
| Tacrolimus | 25 | $3,422 | $137 |
| Ketoconazole | 125 | $2,729 | $22 |
| Clobetasol Propionate | 43 | $2,456 | $57 |
| Metronidazole | 25 | $1,800 | $72 |
| Ciclopirox | 30 | $1,389 | $46 |
| Desonide | 27 | $1,254 | $46 |
| Triamcinolone Acetonide | 70 | $1,236 | $18 |
| Fluocinonide | 25 | $1,155 | $46 |
| Doxycycline Hyclate | 26 | $844 | $32 |
| Hydroxychloroquine Sulfate | 14 | $613 | $44 |
| Mupirocin | 34 | $376 | $11 |
| Clindamycin Phosphate | 11 | $306 | $28 |
| Valacyclovir | 11 | $294 | $27 |
| Minoxidil | 56 | $281 | $5 |
| Hydrocortisone | 26 | $190 | $7 |
| Ciclopirox | 17 | $189 | $11 |
| Finasteride | 12 | $87 | $7 |
2022: 19 drugs
| Taltz | 14 | $89,048 | $6,361 |
| Cosentyx Pen (2 Pens) | 11 | $75,352 | $6,850 |
| Calcipotriene | 15 | $5,785 | $386 |
| Fluorouracil | 41 | $4,604 | $112 |
| Clobetasol Propionate | 21 | $2,040 | $97 |
| Ketoconazole | 97 | $2,020 | $21 |
| Tacrolimus | 14 | $1,660 | $119 |
| Triamcinolone Acetonide | 75 | $1,481 | $20 |
| Tretinoin | 11 | $1,363 | $124 |
| Ciclopirox | 29 | $1,247 | $43 |
| Hydroxychloroquine Sulfate | 17 | $1,218 | $72 |
| Fluocinonide | 21 | $1,106 | $53 |
| Fluocinolone Acetonide | 19 | $801 | $42 |
| Doxycycline Hyclate | 17 | $595 | $35 |
| Valacyclovir | 12 | $310 | $26 |
| Minoxidil | 31 | $193 | $6 |
| Hydrocortisone | 32 | $175 | $5 |
| Mupirocin | 18 | $170 | $9 |
| Finasteride | 16 | $108 | $7 |
2021: 16 drugs
| Taltz | 13 | $76,616 | $5,894 |
| Cosentyx Pen (2 Pens) | 11 | $68,484 | $6,226 |
| Otezla | 13 | $44,803 | $3,446 |
| Tretinoin | 11 | $1,754 | $159 |
| Fluorouracil | 20 | $1,719 | $86 |
| Ketoconazole | 57 | $1,466 | $26 |
| Triamcinolone Acetonide | 43 | $1,440 | $33 |
| Clobetasol Propionate | 13 | $1,120 | $86 |
| Doxycycline Hyclate | 24 | $933 | $39 |
| Fluocinonide | 11 | $705 | $64 |
| Tacrolimus | 11 | $663 | $60 |
| Ciclopirox | 16 | $562 | $35 |
| Fluocinolone Acetonide | 15 | $461 | $31 |
| Ciclopirox | 12 | $228 | $19 |
| Hydrocortisone | 26 | $167 | $6 |
| Mupirocin | 20 | $151 | $8 |
2020: 12 drugs
| Taltz | 13 | $69,130 | $5,318 |
| Fluocinonide | 27 | $2,285 | $85 |
| Triamcinolone Acetonide | 54 | $1,500 | $28 |
| Fluorouracil | 12 | $1,386 | $116 |
| Ketoconazole | 48 | $938 | $20 |
| Doxycycline Hyclate | 25 | $867 | $35 |
| Clobetasol Propionate | 14 | $842 | $60 |
| Ciclopirox | 17 | $507 | $30 |
| Gabapentin | 21 | $248 | $12 |
| Hydroxyzine | 11 | $183 | $17 |
| Mupirocin | 14 | $142 | $10 |
| Hydrocortisone | 19 | $119 | $6 |
2019: 13 drugs
| Fluocinonide | 24 | $1,857 | $77 |
| Doxycycline Hyclate | 32 | $1,416 | $44 |
| Clobetasol Propionate | 21 | $1,392 | $66 |
| Valacyclovir | 17 | $1,312 | $77 |
| Tacrolimus | 13 | $1,222 | $94 |
| Triamcinolone Acetonide | 54 | $1,207 | $22 |
| Ketoconazole | 62 | $1,076 | $17 |
| Alclometasone Dipropionate | 13 | $686 | $53 |
| Clindamycin Phosphate | 13 | $578 | $44 |
| Ciclopirox | 13 | $577 | $44 |
| Hydroxyzine | 15 | $343 | $23 |
| Hydrocortisone | 33 | $193 | $6 |
| Mupirocin | 12 | $135 | $11 |
2018: 12 drugs
| Clobetasol Propionate | 21 | $3,431 | $163 |
| Fluorouracil | 24 | $2,491 | $104 |
| Fluocinonide | 26 | $2,249 | $87 |
| Triamcinolone Acetonide | 78 | $1,874 | $24 |
| Ketoconazole | 68 | $1,572 | $23 |
| Valacyclovir | 18 | $1,345 | $75 |
| Alclometasone Dipropionate | 19 | $855 | $45 |
| Ciclopirox | 23 | $655 | $28 |
| Doxycycline Hyclate | 15 | $499 | $33 |
| Hydroxyzine | 19 | $461 | $24 |
| Hydrocortisone | 41 | $248 | $6 |
| Mupirocin | 20 | $204 | $10 |
2017: 14 drugs
| Desoximetasone | 18 | $5,083 | $282 |
| Fluorouracil | 22 | $2,899 | $132 |
| Fluocinonide | 31 | $2,406 | $78 |
| Clobetasol Propionate | 15 | $2,371 | $158 |
| Ketoconazole | 70 | $2,132 | $30 |
| Triamcinolone Acetonide | 83 | $1,497 | $18 |
| Doxycycline Hyclate | 18 | $1,421 | $79 |
| Alclometasone Dipropionate | 26 | $1,263 | $49 |
| Ciclopirox | 26 | $946 | $36 |
| Hydroxyzine | 26 | $378 | $15 |
| Hydrocortisone | 36 | $214 | $6 |
| Gabapentin | 12 | $165 | $14 |
| Cephalexin | 17 | $160 | $9 |
| Mupirocin | 17 | $112 | $7 |
2016: 10 drugs
| Clobetasol Propionate | 20 | $4,613 | $231 |
| Fluocinonide | 39 | $2,783 | $71 |
| Ketoconazole | 88 | $2,239 | $25 |
| Fluorouracil | 13 | $2,028 | $156 |
| Desonide | 18 | $1,359 | $76 |
| Triamcinolone Acetonide | 62 | $989 | $16 |
| Clindamycin Phosphate | 11 | $855 | $78 |
| Mupirocin | 28 | $246 | $9 |
| Hydroxyzine | 12 | $91 | $8 |
| Hydrocortisone | 11 | $67 | $6 |
2015: 7 drugs
| Clobetasol Propionate | 22 | $4,034 | $183 |
| Fluocinonide | 30 | $2,193 | $73 |
| Desonide | 16 | $1,230 | $77 |
| Ketoconazole | 41 | $1,106 | $27 |
| Triamcinolone Acetonide | 40 | $650 | $16 |
| Mupirocin | 15 | $149 | $10 |
| Gabapentin | 11 | $91 | $8 |
2014: 8 drugs
| Enbrel | 12 | $31,815 | $2,651 |
| Fluorouracil | 28 | $5,010 | $179 |
| Clobetasol Propionate | 19 | $3,650 | $192 |
| Fluocinolone Acetonide | 15 | $2,656 | $177 |
| Fluocinolone Acetonide | 15 | $2,518 | $168 |
| Ketoconazole | 55 | $987 | $18 |
| Fluocinonide | 13 | $697 | $54 |
| Triamcinolone Acetonide | 23 | $327 | $14 |
2013: 4 drugs
| Enbrel | 11 | $26,022 | $2,366 |
| Fluorouracil | 21 | $3,978 | $189 |
| Fluocinolone Acetonide | 18 | $1,847 | $103 |
| Ketoconazole | 39 | $772 | $20 |
Money from drug and device companies
$7,552 in 2025
| 2025 | 2 | 7 | $7,096 | $7,552 |
| 2024 | 1 | 2 | None | $348 |
| 2023 | 1 | 1 | None | $15 |
| 2022 | 1 | 1 | None | $72 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Pharmaceuticals | Libtayo | $7,417 | 6 payments
|
| Janssen Biotech | Tremfya | $136 | 1 payment
|
See all 7 published payments
| Regeneron Pharmaceuticals | Consulting · 2025-12-05 | Libtayo | $887 |
| Regeneron Pharmaceuticals | Consulting · 2025-12-05 | Libtayo | $4,435 |
| Regeneron Pharmaceuticals | Consulting · 2025-12-05 | Libtayo | $1,774 |
| Regeneron Pharmaceuticals | Meals · 2025-11-13 | Libtayo | $144 |
| Regeneron Pharmaceuticals | Meals · 2025-11-13 | Libtayo | $36 |
| Regeneron Pharmaceuticals | Meals · 2025-11-13 | Libtayo | $141 |
| Janssen Biotech | Meals · 2025-04-25 | Tremfya | $136 |
See earlier years (2024, 2023, 2022)
2024: $348
| Abbvie | Skyrizi | $348 | 2 payments
|
2023: $15
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $72
| Pfizer | Cibinqo | $72 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1396057105
- Licence
- CA A118309California A118309: Current · expires 2027-03-31
- Group
- New York University
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 900 Blake Wilbur Dr, W1006, Palo Alto, CA, 94304
- NPI first listed
- 2010-07-09
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 900 Blake Wilbur Dr, Palo Alto, CA, 94304